To determine whether the administration of 1.5 million units of streptokinase intravenously within 4 hours of the onset of acute ischemic stroke would reduce morbidity and mortality at 3 months and whether outcomes may be better for those receiving therapy within 3 hours of stroke onset compared with those receiving it after 3 hours.
- Streptokinase (Streptase®)Drug
Intervention Desc: Thrombolytic agent
Randomized, double-blind, placebo-controlled trial involving 340 patients at 40 centers throughout Australia.
Administration of 1.5 million units of streptokinase or placebo intravenously in 100 mL of normal saline over 1 hour with 3 month follow-up.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Combined death and disability score (Barthel index <60) 3 months after the stroke.|